Biogen Gets Patent Extension On MS Drug To 2026
NEW YORK (AP) ¿ Biogen Idec Inc. has essentially received a 13-year patent extension on its biggest moneymaker, the multiple sclerosis drug Avonex, according to a Securities and Exchange Commission filing Tuesday.
Key patents dealing with the production of Avonex are scheduled to expire in 2013. But in the regulatory filing, Biogen said it has received a patent for the drug's use in treating a viral condition, disease, cancer or tumor until September 2026. The so-called method of use patent also includes the use of Avonex as a multiple sclerosis drug.
Sales of Avonex reached $591.2 million during the most recent quarter.
The company would not say whether this new patent blocks any potential competitors seeking to bring a generic version of the drug to market between 2013 and 2026.The patent win comes as the debate over a pathway for copies of pricey biotechnology-based drugs continues to work its way through Congress. Currently, there is no system set up for drug developers to make generic equivalents of biotechnology-based treatments. Unlike their chemical-based counterparts, biotech drugs are made using living organisms, making the production process more complicated than just copying a formula.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV